Indium-labeled macrocyclic conjugates of naltrindole: High-affinity radioligands for in vivo studies of peripheral δ opioid receptors

Journal of Medicinal Chemistry

Volumn 50, Issue 9, 2007, Pages 2144-2156

  Duval, Romain A ^a,b   Allmon, Rachel L ^a,b   Lever, John R ^a,b  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; DELTA OPIATE RECEPTOR; INDIUM 111; MACROCYCLIC COMPOUND; NALTREXONE; NALTRINDOLE; RADIOLIGAND;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPLEX FORMATION; CONJUGATE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; QUANTUM YIELD; RADIOACTIVITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ALDEHYDES; ANIMALS; AUTORADIOGRAPHY; BINDING, COMPETITIVE; GUINEA PIGS; HETEROCYCLIC COMPOUNDS, 1-RING; INDIUM RADIOISOTOPES; LIGANDS; MACROCYCLIC COMPOUNDS; MALE; MICE; NALTREXONE; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RECEPTORS, OPIOID, DELTA; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 34247646912     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0700013     Document Type: Article

References (72)

1. Lever, J. R. PET and SPECT imaging of the opioid system: receptors, radioligands and avenues for drug discovery and development. Curr. Pharm. Des. 2007, 13, 33-49.
2. 11C]MeNTI): a radioligand for positron emission tomographic studies of delta opioid receptors. J. Label. Compd. Radiopharm. 1995, 36, 137-145.
3. 11C]methyl) naltrindole to δ-opioid receptors in mouse brain. Eur. J. Pharmacol. 1992, 216, 459-460.
4. 11C]methyl)- naltrindole and PET. Synapse 1996, 24, 19-28.
5. 11C]methyl)naltrindole and positron emission tomography. J. Cereb. Blood Flow Metab. 1999, 19, 956-966.
6. Madar, I.; Lesser, R. P.; Krauss, G.; Zubieta, J.-K.; Lever, J. R.; Kinter, C. M.; Ravert, H. T.; Musachio, J. L.; Mathews, W. B.; Dannals, R. F.; Frost, J. J. Imaging of delta- and mu-opioid receptors in temporal lobe epilepsy by positron emission tomography. Ann. Neurol. 1997, 41, 358-367.
7. Portoghese, P. S.; Sultana, M.; Takemori, A. E. Design of peptidomimetic δ opioid receptor antagonists using the message-address concept. J. Med. Chem. 1990, 33, 1714-1720.
8. 18F]FEtNTI): a radioligand for positron emission tomographic studies of delta opioid receptors. J. Label. Compd. Radiopharm. 1999, 42, 43-54.
9. (b) Clayson, J.; Jales, A.; Tyacke, R. J.; Hudson, A. L.; Nutt, D. J.; Lewis, J. W.; Husbands, S. M. Selective δ-opioid receptor ligands: potential PET ligands based on naltrindole. Bioorg. Med. Chem. Lett. 2001, 11, 939-943.
10. 18F]BNTI): a potential PET imaging agent for DOP receptors. J. Label. Compd. Radiopharm. 2006, 49, 857-866.
11. Lever, J. R.; Mathews, W. B.; Allmon, R. L.; Kinter, C. M.; Rauseo, P. A.; Scheffel, U. Synthesis and binding studies of ligands selective for delta opioid receptors: radioiodinated (E)- and (Z)- N1′-(3-iodoallyl)naltrindole. J. Label. Compd. Radiopharm. 2003, 46, S36.
12. Korlipara, V.; Ells, J.; Wang, J.; Tam, S.; Eide, R.; Portoghese, P. Fluorescent N-benzylnaltrindole analogues as potential delta opioid receptor selective probes. Eur. J. Med. Chem. 1997, 32, 171-174.
13. Waterhouse, R. N. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol. Imaging Biol. 2003, 5, 376-389.
14. (a) Campa, M. J.; Schreiber, G.; Bepler, G.; Bishop, M. J.; McNutt, R. W.; Chang, K. J.; Patz, E. F. Characterization of delta opioid receptors in lung cancer using a novel nonpeptidic ligand. Cancer Res. 1996, 56, 1695-1701.
15. (b) Schreiber, G.; Campa, M. J.; Prabhakar, S.; O'Briant, K.; Bepler, G.; Patz, E. F., Jr. Molecular characterization of the human delta opioid receptor in lung cancer. Anticancer Res. 1998, 18, 1787-1792.
16. (c) Tegeder, I.; Geisslinger, G. Opioids as modulators of cell death and survival - unraveling mechanisms and revealing new indications. Pharmacol. Rev. 2004, 56, 351-369.
17. (d) Fichna, J.; Janecka, A. Opioid peptides in cancer. Cancer Metastasis Rev. 2004, 23, 351-366.
18. (a) Peart, J. N.; Gross, E. R.; Gross, G. J. Opioid-induced preconditioning: recent advances and future perspectives. Vasc. Pharmacol. 2005, 42, 211-218.
19. (b) Lendeckel, U.; Muller, C.; Rocken, C.; Laube, B.; Tager, M.; Huth, C.; Klein, H. U.; Goette, A. Expression of opioid receptor subtypes and their ligands in fibrillating human atria. Pacing Clin. Electrophvsiol. 2005, 28, S275-S279.
20. (c) Watson, M. J.; Holt, J. D.; O'Neill, S. J.; Wei, K.; Pendergast, W.; Gross, G. J.; Gengo, P. J.; Chang, K. J. ARD-353 [4-((2R,5S)-4- (R)-(4-diethylcarbamoylphenyl)(3-hydroxyphenyl) methyl)-2,5- dimethylpiperazin-1-ylmethyl)benzoic acid], a novel nonpeptide δ receptor agonist, reduces myocardial infarct size without central effects. J. Pharmacol. Exp. Ther. 2006, 316, 423-430.
21. (a) Mehendale, S. R.; Yuana, C.-S. Opioid-induced gastrointestinal dysfunction. Dig. Dis. 2006, 24, 105-112.
22. (b) Philippe, D.; Chakass, D.; Thuru, X.; Zerbib, P.; Tsicopoulos, A.; Geboes, K.; Bulois, P.; Breisse, M.; Vorng, H.; Gay, J.; Colombel, J.-F.; Desreumaux, P.; Chamaillard, M. Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation. Gut 2006, 55, 815-823.
23. (c) Pol, O.; Palacio, J. R.; Puig, M. M. The expression of δ- and κ-opioid receptor is enhanced during intestinal inflammation in mice. J. Pharmacol. Exp. Ther. 2003, 306, 455-462.
24. (a) Stein, C.; Schäfer, M.; Machelska, H. Attacking pain at its source: new perspectives on opioids. Nat. Med. 2003, 9, 1003-1008.
25. (b) Eisenach, J. C.; Carpenter, R.; Curry, R. Analgesia from a peripherally active κ-opioid receptor agonist in patients with chronic pancreatitis. Pain 2003, 101, 89-95.
26. Villemagne, P. S. R.; Dannals, R. F.; Ravert, H. T.; Frost, J. J. PET imaging of human cardiac opioid receptors. Eur. J. Nucl. Med. Mol. Imaging 2002, 29, 1385-1388.
27. Madar, I.; Bencherif, B.; Lever, J.; Heitmiller, R. F.; Yang, S. C.; Brock, M.; Brahmer, J.; Ravert, H.; Dannals, R.; Frost, J. J. Imaging δ- and μ-opioid receptors by PET in lung carcinoma patients. J. Nucl. Med. 2007, 48, 207-213.
28. Villemagne, P. M.; Bluemke, D. A.; Dannals, R. F.; Ravert, H. T.; Frost, J. J. Imaging opioid receptors in human breast cancer by PET. J. Nucl. Med. 2002, 43S, 280P.
29. (a) Lever, S. Z.; Lydon, J. D.; Cutler, C. S.; Jurisson, S. S. Radioactive Metals in Imaging and Therapy. In Comprehensive Coordination Chemistry II; McCleverty, J. A., Meyer, T. J., Eds.; Vol. 9, Chapter 20, Ward, M. D. Ed.; Elsevier Science: Oxford, U.K., 2003; pp 883-911.
30. (b) Anderson, C. J.; Welch, M. J. Radiometal-labeled agents (non-technetium) for diagnostic imaging. Chem. Rev. 1999, 99, 2219-2234.
31. (a) Jurisson, S. S.; Lydon, J. D. Potential technetium small molecule radiopharmaceuticals. Chem. Rev. 1999, 99, 2205-2218.
32. (b) Schibli, R.; Schubiger, P. A. Current use and future potential of organometallic radiopharmaceuticals. Eur. J. Nucl. Med. Mol. Imaging 2002, 29, 1529-1542.
33. (c) Storr, T.; Thompson, K. H.; Orvig, C. Design of targeting ligands in medicinal inorganic chemistry. Chem. Soc. Rev. 2006, 35, 534-544.
34. (d) Liang, F.; Wan, S.; Li, Z.; Xiong, X.; Yang, L.; Zhou, X.; Wu, C. Medical applications of macrocyclic polyamines. Curr. Med. Chem. 2006, 13, 711-727.
35. A preliminary account of one aspect of this work has appeared: Lever, J. R.; Duval, R. A.; Allmon, R. L.; Carmack, T. L.; Watkinson, L. D. Synthesis and pharmacological studies of an indium-labeled DOTA conjugate of naltrindole having high affinity for delta opioid receptors. In Technetium, Rhenium and other Metals in Chemistry and Nuclear Medicine, 7th ed.; Mazzi, U., Ed.; SGE Editoriali: Padova, Italy, 2006; pp 207-210.
36. Keire, D. A.; Jang, Y.-H.; Li, L.; Dasgupta, S.; Goddard, W. A., III; Shively, J. E. Chelators for radioimmunotherapy: I. NMR and ab initio calculation studies on 1,4,7,10-tetra(carboxyethyl)-1,4,7,10- tetraazacyclododecane (DO4Pr) and 1,4,7-tris(carboxymethyl)-10-(carboxyethyl)-1, 4,7,10-tetraazacyclododecane (DO3AlPr). Inorg. Chem. 2001, 40, 4310-4318.
37. Abdel-Magid, A. F.; Carson, K. G.; Harris, B. D.; Maryanoff, C. A.; Shah, R. D. Reductive amination of aldehydes and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive amination procedures. J. Org. Chem. 1996, 61, 3849-3862.
38. 111In-labeled DOTA-biomolecule conjugates. Inorg. Chem. 2003, 42, 8831-8837.
39. Hansch, C. A quantitative approach to biochemical structure-activity relationships. Acc. Chem. Res. 1969, 2, 232-239.
40. Noy, N.; Zakim, D. Physical-chemical basis for the uptake of organic compounds by cells. In Hepatic Transport and Bile Secretion: Physiology and Pathophysiology; Tavoloni, N., Berk, P. D., Eds.; Raven Press: New York, 1993; pp 313-335.
41. 3H]naltrindole binding to delta opioid receptors in mouse brain and mouse vas deferens: evidence for delta opioid receptor heterogeneity. J. Pharmacol. Exp. Ther. 1994, 268, 836-846.
42. 3H]naltrindole: a potent and selective ligand for labeling δ-opioid receptors. Brain Res. 1993, 604, 160-164.
43. 3 aromatic ring in cyclic δ opioid receptor selective dermorphind/deltorphin tetrapeptide analogues: electronic and lipophilic requirements for receptor affinity. J. Med. Chem. 1992, 35, 1535-1541.
44. Coop, A.; Rothman, R. B.; Dersch, C.; Partilla, J.; Porreca, F.; Davis, P.; Jacobson, A. E.; Rice, K. C. δ Opioid affinity and selectivity of 4-hydroxy-3-methoxyindolomorphinan analogues related to naltrindole. J. Med. Chem. 1999, 42, 1673-1679.
45. Casy, A. F.; Parfitt, R. T. Opioid Analgesics, Chemistry and Receptors; Plenum Press: New York, 1986; pp 470-472.
46. (a) Kane, B. E.; Svensson, B.; Ferguson, D. M. Molecular recognition of opioid receptor ligands. AAPS J. 2006, 8, E126-137.
47. (b) Valiquette, M.; Vu, H. K.; Yue, S. Y.; Wahlestedt, C.; Walker, P. Involvement of Trp-284, Val-296, and Val-297 of the human δ-opioid receptor in binding of δ-selective ligands. J. Biol. Chem. 1996, 271, 18789-18796.
48. (c) Metzger, T. G.; Paterlini, M. G.; Ferguson, D. M.; Portoghese, P. S. Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the 'address' recognition locus. J. Med. Chem. 2001, 44, 857-862.
49. Lever, J. R.; Gustafson, J. L.; Xu, R.; Allmon, R. L.; Lever, S. Z. σ1 and σ2 receptor binding affinity and selectivity of SA4503 and fluoroethyl SA4503. Synapse 2006, 59, 350-358.
50. Kenakin, T. Pharmacologic Analysis of Drug-Receptor Interaction, 2nd ed.; Raven Press: New York, 1993; pp 137-175.
51. (a) Chivers, J. K.; Gommeren, W.; Leysen, J. E.; Jenner, P.; Marsden, C. D. Comparison of the in-vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors. J. Pharm. Pharmacol. 1987, 40, 415-421.
52. (b) Blin, O. A comparative review of new antipsychotics. Can. J. Psychiatry 1999, 44, 235-244.
53. 2]Deltorphin-I: a high affinity, delta-selective opioid receptor ligand. Peptides 1991, 12, 825-830.
54. 3H]naltrindole binding sites in the rat brain. Brain Res. 1993, 602, 138-142.
55. Zimlichman, R.; Gefel, D.; Eliahou, H.; Matas, Z.; Rosen, B.; Gass, S.; Ela, C.; Eilam, Y.; Vogel, Z.; Barg, J. Expression of opioid receptors during heart ontogeny in normotensive and hypertensive rats. Circulation 1996, 93, 1020-1025.
56. Khawaja, X. Z.; Green, I. C.; Thorpe, J. R.; Titheradge, M. A. The occurrence and receptor specificity of endogenous opioid peptides within the pancreas and liver of the rat. Comparison with brain. Biochem. J. 1990, 267, 233-240.
57. Boyadjieva, N. I.; Chaturvedi, K.; Poplawski, M. M.; Sarkar, D. K. Opioid antagonist naltrexone disrupts feedback interaction between μ and δ opioid receptors in splenocytes to prevent alcohol inhibition of NK cell function. J. Immunol. 2004, 173, 42-49.
58. (a) Nishimura, E.; Buchan, A. M.; McIntosh, C. H. Autoradiographic localization of opioid receptors in the rat stomach. Neurosci. Lett. 1984, 50, 73-78.
59. (b) Nishimura, E.; Buchan, A. M.; McIntosh, C. H. Autoradiographic localization of μ- and δ-type opioid receptors in the gastrointestinal tract of the rat and guinea pig. Gastroenterology 1986, 91, 1084-1094.
60. (c) De Luca, A.; Coupar, I. M. Insights into opioid action in the intestinal tract. Pharmacol. Ther. 1996, 69, 103-115.
61. (d) Townsend, D., IV; Brown, D. R. Predominance of δ-opioid-binding sites in the porcine enteric nervous system. J. Pharmacol. Exp. Ther. 2002, 300, 900-909.
62. Evans, A. A.; Tunnicliffe, G.; Knights, P.; Bailey, C. J.; Smith, M. E. Delta opioid receptors mediate glucose uptake in skeletal muscles of lean and obese-diabetic (ob/ob) mice. Metabolism 2001, 50, 1402-1408.
63. Oude Elferink, R. P. J.; Meijer, D. K. F.; Kuipers, F.; Jansen, P. L. M.; Groen, A. K.; Groothuis, G. M. M. Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport. Biochim. Biophys. Acta. 1995, 1241, 215-268.
64. Rivory, L. P.; Avent, K. M.; Pond, S. M. Effects of lipophilicity and protein binding on the hepatocellular uptake and hepatic disposition of two anthracyclines, doxorubicin and iododoxorubicin. Cancer Chemother. Pharmacol 1996, 38, 439-445.
65. 3H]U-69,593 to airway and pulmonary tissues of normal and sensitized rats. Peptides 1997, 18, 1603-1608.
66. Mercadante, S; Arcuri, E. Opioids and renal function. J. Pain 2004, 5, 2-19.
67. Sezen, S. F.; Kenigs, V. A.; Kapusta, D. R. Renal excretory responses produced by the delta opioid agonist, BW373U86, in conscious rats. J. Pharmacol. Exp. Ther. 1998, 287, 238-245.
68. Wittert, G.; Hope, P.; Pyle, D. Tissue distribution of opioid receptor gene expression in the rat. Biochem. Biophys. Res. Commun. 1996, 218, 877-881.
69. Bidlack, J. M. Detection and function of opioid receptors on cells from the immune system. Clin. Diagn. Lab. Immunol. 2000, 7, 719-723.
70. 5] enkephalin after intraperitoneal, intravenous, oral and subcutaneous administration. J. Pharmacol. Exp. Ther. 1992, 263, 1308-1316.
71. 125I]-ITIPP(ψ). Nucl. Med. Biol. 2001, 28, 375-381.
72. Lever, J. R.; Watson, T. A.; Owen, N. K.; Fitzsimmons, J. M.; Mazuru, D. G.; Hoffman, T. J. In vivo localization of opioid receptors on human breast cancer xenografts in SCID mice. J. Nucl. Med. 2002, 43S, 282P.